Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VEOPOZ safely and effectively. See full prescribing information for VEOPOZ. VEOPOZ® (pozelimab-bbfg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
- generic_name
- pozelimab
- product_names
- Pozelimab
- ndc
- 61755-014, 61755-014-00, 61755-014-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en